Twitter | Search | |
Stemina Biomarker
Stemina Biomarker Discovery is a metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety
419
Tweets
555
Following
537
Followers
Tweets
Stemina Biomarker Oct 18
Our assay Cardio quickPredict indicates the cardiotoxicity potential of drug candidates and other lead compounds. We presented a poster and oral session highlighted the assay. Download now:
Reply Retweet Like
Stemina Biomarker Oct 16
Autumn is in full swing. The leaves are stunning! What do the different colors signify, in terms of their chemical compounds? Check out this chart from !
Reply Retweet Like
Stemina Biomarker Oct 11
We presented a poster at , the annual meeting of , last week. The research featured our new cardiotoxicity assay, Cardio quickPredict. Download the poster and slides:
Reply Retweet Like
Stemina Biomarker Oct 8
California will become the first state to ban the sale of cosmetics tested on animals, a move that could inspire changes in other US policies. The new law will take effect on 1/1/20.
Reply Retweet Like
Stemina Biomarker Oct 4
A recent paper evaluates the use of human iPSC-derived cardiomyocytes to detect drug-induced proarrhythmic effects; the results show the potential of alternative models for cardiotoxicity testing.
Reply Retweet Like
Stemina Biomarker Oct 2
Visit Poster #0037, Prediction of Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, today! Author-attended 1–2 PM by Assoc Dir of Toxicology Jessica Palmer.
Reply Retweet Like
Stemina Biomarker Oct 1
Our poster on the new cardiotoxicity assay is up at ! Lead author Jessica Palmer will be at Poster #0037 today, 3:15 – 3:30 PM, and tomorrow, 1-2 PM.
Reply Retweet Like
Stemina Biomarker Oct 1
We’re excited to participate in ! Up first: Invited Oral Communication 2 – Impact of Human Induced Pluripotent Stem Cells on In Vitro Cardiac and CNS Safety Assessment. We’re up 2:15 – 2:30 PM. Be there!
Reply Retweet Like
Stemina Biomarker Sep 27
One study behind Stemina’s new cardiotoxicity assay will presented at the . “Prediction of Cardiotoxicity Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes,” 10/1, 2:15 PM.
Reply Retweet Like
Stemina Biomarker Sep 25
Is collaboration and sharing credit an issue in your lab? This piece, published in , gives tips on keeping the peace and creating resources for everyone to use.
Reply Retweet Like
Stemina Biomarker Sep 20
Stemina will attend . We will present a present a poster (on display 9/30 – 10/2) and an oral presentation (10/1). Stay tuned for further details!
Reply Retweet Like
Stemina Biomarker Sep 19
Thanks for the shout-out, !
Reply Retweet Like
Stemina Biomarker Sep 18
The NICHD is researching how opioids impact children and pregnant and reproductive-age women through many ongoing studies. A quick overview:
Reply Retweet Like
Stemina Biomarker Sep 13
Thank you for covering our story, !
Reply Retweet Like
Stemina Biomarker Sep 11
Attending today? Check out the panel at 5 PM -- Public-Private Partnerships as a mechanism for implementing new approaches. Our own Jessica Palmer is on the panel!
Reply Retweet Like
Stemina Biomarker Sep 11
Right now, our own Jessica Palmer, Associate Director of Toxicology, is presenting a poster at the annual meeting in Baltimore. If you're attending, go check it out!
Reply Retweet Like
Stemina Biomarker Sep 7
Thank you, ! It feels huge to us, too. We've been working on this significant research for years and we're excited to share our findings.
Reply Retweet Like
Stemina Biomarker Sep 6
Our division has big news today – Its paper, published online in “Biological Psychiatry,” reveals a link between the way some children process proteins and the likelihood they will be diagnosed with .
Reply Retweet Like
Stemina Biomarker Sep 5
Systematic reviews are more rigorous and can lead to removal (or at least acknowledgement) of reviewer bias. In other words, systematic review is a good counterpart to creating and publishing quality science.
Reply Retweet Like
Stemina Biomarker Sep 4
Our team is growing. Join us! NeuroPointDX, a division of Stemina, is seeking a Customer Care Specialist to help patient families, health care providers, and phlebotomists. Apply now:
Reply Retweet Like